Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis

Deferasirox (DSX) is the principal option currently available for iron-chelation-therapy (ICT), principally in the management of myelodysplastic syndromes (MDS), while in primary myelofibrosis (PMF) the expertise is limited. We analyzed our experience in 10 PMF with transfusion-dependent anemia, tre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Elli, Elena Maria, Belotti, Angelo, Aroldi, Andrea, Parma, Matteo, Pioltelli, Pietro, Pogliani, Enrico Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Università Cattolica del Sacro Cuore 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063602/
https://ncbi.nlm.nih.gov/pubmed/24959339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2014.042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados